Fundraising Fox
RS BioTherapeutics
Cumberland, US · Founded 2021 · Delaware corporation
Find your way into RS BioTherapeutics
Sign up to see every warm intro you have to RS BioTherapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the RS BioTherapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
RS BioTherapeutics is a biopharmaceutical company developing therapeutics for respiratory diseases characterized by pulmonary inflammation. Its lead compound, RSBT-001, is a cannabinoid-based, first-in-class alternative to corticosteroids in development for conditions including COPD, idiopathic pulmonary fibrosis, and pulmonary arterial hypertension.
Founders & leadership
HD
H. Dean HartChief Executive Officer2022–2025H. Dean Hart held leadership positions in the pharmaceutical industry managing multi-billion-dollar brands before founding consulting and coaching practices focused on executive development and commercial strategy for life sciences organizations.
CR
Curtis RhineChief Financial Officer2023–2025Curtis Rhine is an executive with experience in finance and accounting across multiple disciplines, including financial planning, budgeting, treasury management, and reporting. He has held leadership roles at companies of various sizes and has led operational improvements including ERP implementations and family office financial management.
DF
Dustin FreasNamed on SEC filing
Board
DF
David FreasBoard director
Reported raises · per SEC filings
Form D private placements$1.9M disclosed across 4 rounds · 2022–2024
▶$20KraisedOct 2024 · 1 investors · Other Health CareRule 506(b)
▶$20KraisedOct 2024 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Michael GuzmanExecutive Officer
- H. Dean HartExecutive Officer
- Curtis RhineExecutive Officer
- Justin MolignoniExecutive Officer, Director
- David FreasDirector
- Offering amount
- $2M
- Amount sold
- $20K
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.1MraisedOct 2023 · 5 investors · PharmaceuticalsRule 506(b)
▶$1.1MraisedOct 2023 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Curtis RhineExecutive Officer
- Michael GuzmanExecutive Officer
- H. Dean HartExecutive Officer
- David FreasDirector
- Justin MolignoniExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $1.1M
- Minimum investment
- $50K
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$100KraisedMar 2023 · 1 investors · PharmaceuticalsRule 506(b)
▶$100KraisedMar 2023 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- H. Dean HartExecutive Officer
- Curtis RhineExecutive Officer
- Dustin FreasDirector
- Justin MolignoniExecutive Officer, Director
- Michael GuzmanExecutive Officer
- Offering amount
- $10M
- Amount sold
- $100K
- Minimum investment
- $50K
- Proceeds to insiders
- $1.6M
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$685KraisedJun 2022 · 6 investors · PharmaceuticalsRule 506(b)
▶$685KraisedJun 2022 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Justin MolignoniExecutive Officer, Director
- Michael GuzmanExecutive Officer
- H. Dean HartExecutive Officer
- Dustin FreasExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $685K
- Minimum investment
- $50K
- Proceeds to insiders
- $886.7K
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Sarepta TherapeuticsSarepta develops precision genetic medicines for people with rare diseases, with a focus on rare neuromuscular conditions. The company also runs an investigator-initiated studies program that funds independent clinical and non-clinical research in its therapeutic areas.
RisetherapeuticsRise Therapeutics develops oral immunotherapies, called Oral Immune BioModulators, using a synthetic biology-based drug design approach to treat autoimmune diseases and cancer. The company combines immunology research with in-house clinical GMP manufacturing and regulatory expertise to advance its pipeline through clinical validation.
Companies working in the same space as RS BioTherapeutics.
In the news
Frequently asked questions
- What does RS BioTherapeutics do?
- RS BioTherapeutics is a biopharmaceutical company developing therapeutics for respiratory diseases characterized by pulmonary inflammation. Its lead compound, RSBT-001, is a cannabinoid-based, first-in-class alternative to corticosteroids in development for conditions including COPD, idiopathic pulmonary fibrosis, and pulmonary arterial hypertension.
- How much funding has RS BioTherapeutics raised?
- RS BioTherapeutics has disclosed $1.9M raised across 4 rounds.
- Where is RS BioTherapeutics headquartered?
- RS BioTherapeutics is headquartered in Cumberland, US.